Mar 14th 2013 - Edison Investment Research today published a report on BioInvent entitled "Focused Onto Cancer". In summary, the report says:
FY12 results showed revenues and grants of SEK55.5m with costs of SEK246.6m, including SEK49.2m of provisions and restructuring costs. The company has restructured to give a stated cost base of SEK75m before revenues in 2013. There was SEK100m of cash on 31 December. The BI-505 Phase I dose-escalating and safety study in relapsed and refractory multiple myeloma (MM) indicated a dose of 10mg/kg. BI-505 will progress to a small Phase IIa during 2013. BioInvent intends to partner BI-505 in 2014. Two preclinical antibodies have entered development.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »
